Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In vitro lymphocyte stimulation by mitomycin-C-blocked tumor cells has been used to demonstrate tumor-specific antigens in syngeneic murine systems and to follow the evolution of tumor immunity with the tumor-bearing state. Mitomycin-blocked tumor cells stimulated syngeneic lymphocytes from normal mice, from those bearing small tumors (less than 1 cm in diameter) and from tumor-immune mice, sensitized by tumor-cell inoculation and subsequent tumor removal, to undergo increased DNA synthesis as measured by the incorporation of tritiated thymidine. However, lymph-node cells from mice bearing tumors over 1 cm in diameter appeared to be maximally stimulated in vivo and incapable of further stimulation by the same tumor cells in vitro. This was reflected by the progressively increasing background levels of nucleic acid synthesis with the length of tumor-bearing and the size of the tumor. Although lymph-node cells from mice with large tumors did not respond to the same tumor cells in vitro, they did have normal responses to
PHA
. Within 7-14 days of surgical removal of the tumor, specific lymphocyte responsiveness and background activity returned to previous normal levels, but reinoculation with 10-6 tumor cells resulted in progressive
tumor growth
and loss of specific in vitro responsiveness when the second tumor had reached the critical size of 1 cm in diameter. Brief exposure of tumor-immune lymph-node cells to a soluble antigen extract of the same tumor resulted in a marked increase in DNA synthetic activity compared to that obtained after exposure to a different tumor extract, muscle extract or medium alone underwent stimulation when cultured with mitomycin-blocked tumor cells. However, normally responsive tumor-immune lymph-node cells, after brief exposure to a soluble antigen extract of the same tumor, initially underwent increased DNA synthesis, but were incapable of further stimulation by mitomycin-blocked tumor cells. Tumor antigen, alone or complexed with antibody, was also demonstrated in the sera of mice bearing large tumors and is thought to be responsible for the refractoriness of lymph-node cells from these mice to further stimulation in vitro. These experiments demonstrate that tumor size and the consequent antigen load to which the tumor-bearing animals is subjected have a profound effect on tumor-specific lymphocyte responsiveness.
...
PMID:Refractoriness of lymph-node cells from tumour-bearing animals. 4 43
Twenty-one patients with advanced malignancies who had exhausted or refused conventional modalities of treatment were entered in a Phase I toxicology trial of active specific intralymphatic immunotherapy (ASILI). The patients were immunized with 1 X 10(7) to 1.2 X 10(8) viable autochthonous or allogeneic irradiated tumor cells intralymphatically each month and received no other antineoplastic treatment. To date, 274 intralymphatic injections have been performed and except for one case of bacterial lymphangitis, no adverse side effects have been observed. ASILI did not significantly alter peripheral blood lymphocyte counts, absolute E-rosette forming cell levels, or EA-rosette forming cell levels.
PHA
reactivity of peripheral blood lymphocytes increased slightly in all but one patient tested. Seven out of nine patients who had not had delayed hypersensitivity to recall antigens developed positive reactions following ASILI. Sixteen out of twenty patients tested also developed reactivity to their immunizing cells after treatment. Objective regression (greater than 50% reduction of tumor mass) was observed in five out of nineteen evaluable patients. Six patient showed stabilization of
tumor growth
and eight patients continued to progress under treatment.
...
PMID:A phase I study of active specific intralymphatic immunotherapy (ASILI). 7 18
The effect of thymosin on suppressor-cell function was evaluated in vivo in a murine tumor system and in vitro on human lymphocytes. In mice, the Lewis tumor system was used. We showed that splenocytes from tumor-bearing animals were able to enhance
tumor growth
in a syngeneic system. This enhancement was similar when thymocytes from tumor-bearing animals were used and disappeared after anti-Thy 1-2 antiserum treatment, suggesting a T-dependence. Treatment of the tumor-growth-enhancing lymphocytes with corticosteroids or irradiation caused this effect to disappear completely suggesting that the tumor-growth-enhancing T-lymphocytes were suppressor T-cells. Furthermore thymosin (fraction 5)-treated, tumor-growth-enhancing T-lymphocytes were not able to enhance
tumor growth
and even significantly decreased it. In the human system we showed that Con A-stimulated lymphocytes were able to suppress the response of normal lymphocytes to
PHA
, PWM, and Con A, and in MLC. This effect was significantly blocked in presence of thymosin fraction 5.
...
PMID:Thymosin modulation of suppressor function in mice and man. 16 Nov 54
The present communication is a continuation of earlier studies which indicated that interaction between syngeneic tumors and those lymphocytes in the early stages of thymic processing can result in enhanced
tumor growth
in vivo. The thymocytes involved in this tumor enhancement were found previously in the rapidly dividing subpopulation of subcapsular cortical thymocytes, both in the untreated thymus and in the thymus undergoing repopulation after cortisone depletion. In the present experiments we have isolated this small subpopulation of early thymocytes. After cortisone injection such cells could be separated from the medullary cortisone-resistant thymocytes since the latter cells exhibit a high level of surface H-2 antigens and were thus lysed preferentially by anti-H-2 serum and complement. The repopulating subcapsular early thymocytes, which were resistant to this treatment, were incapable of responding to
PHA
while their basal proliferation rate was undiminished, and the majority of the cells were found to be dividing. When such low H-2 early thymocytes were injected together with three different tumors into syngeneic mice their tumor-enhancing activity was evident. It is clear that such early thymocytes are not devoid of biologic reactivity and their release from the thymus could have decisive results.
...
PMID:Opposing reactivities of subpopulations of T lymphocytes toward syngeneic tumor cells: separation of early thymocytes. 30 21
The author reports the results of studying 311 reactions of lymphocyte blasttransformation, 74 reactions of spontaneous rosette-formation and 186 reactions of plaque-formation in 184 patients with different stages of cervical cancer. It was found that in the tumor progression cell immunity indices are lowered and the degree of the lowering is dependent on the form of
tumor growth
. Radiotherapy results in the enhancement of autoantibody-formation processes and suppresses the response of lymphocytes to
PHA
found to be mostly pronounced in patients with advanced cancer. The blasttransformation reaction correlates well with the number of peripheral blood lymphocytes, and during radiotherapy the former slows down before the routinely revealed lymphopenia, that allows using this reaction to prognosticate lymphopenia. The most large amounts of plaque-forming blood cells were detected in patients with radiation injuries of the adjacent to the uterus organs of the small pelvis. Use of lymphocyte blasttrasformation reaction and quantitation of plaque-forming blood cells may provide the grounds for the individual application of radiotherapy for cervical cancer to increase its effectiveness.
...
PMID:[Control of the immunological reactivity in cervical cancer in the process of radiation therapy]. 31 45
Spleens from BALB/c mice transplanted with mammary tumors display a significant increase in the percentage of lymphocytes bearing complement receptors (CRL) while the percentage of cells bearing surface immunoglobulins (SIg) remains unchanged in comparison with that in spleens from normal animals. Upon separation on nylon columns, the increase in CRL in the spleens from tumor-bearing mice was limited to the non-adherent cell population. Simultaneous maker analysis disclosed that these CRL lacked detectable SIg. Indirect immunofluorescence indicated that these cells possessed theta antigen. Absence of SIg and the presence of theta antigen coupled with the restricted occurrence of these cells in the nylon-non-adherent population which responded to
PHA
and Con A but not to LPS indicate that these cells may constitute a subset of T cells. The paucity of this subpopulation of spleen lymphocytes in normal spleen suggests that their emergence is related to
tumor growth
.
...
PMID:Emergence of a subpopulation of lymphocytes bearing theta antigen and complement receptor during tumor growth. 78 59
Groups of inbred C3H mice selected on the basis of strong or weak PPD reactions after sensitization with complete Freund adjuvant had significantly different reactions to
PHA
. The growth rate of a methylcholanthrene-induced tumor, previously shown to elicit a cell-mediated immune response, was significantly different in these two groups of mice. The basis for the marked variation observed between members of an inbred mouse strain in response to CFA is not understood but may bear an important potential relationship to
tumor growth
.
...
PMID:Relationship between the response to complete freund adjuvant, phytohemagglutinin, and subsequent tumor growth in mice. 118 9
Work done in our laboratories, using a murine model, indicates that suppression of host immune responses might be due to secretion of soluble factors by tumor cells. The H238 cells (BALB/c embryonic fibroblasts transformed by UV-inactivated herpes simplex virus Type 2) exhibit progressive
tumor growth
with subsequent decrease in lymphoproliferation. To further study the suppressive effects of a tumor, H238 conditioned medium (CM) was tested for its ability to block murine and human mitogenic and allogeneic lymphocyte responses.
PHA
, Con A and LPS were used as mitogens. Lymphoproliferation, in the presence of increasing amounts of H238 CM, resulted in a greater degree of suppression of [3H]thymidine ([3H]Tdr) uptake, in both human and mouse systems. The kinetics of proliferation in the presence of concentrated H238 CM (cCM) showed that depression was evident regardless of the time of cCM addition, thereby affecting it at any stage of the cell cycle. Treatment of H238 cCM using acid (pH 2.3), base (pH 9.6), trypsin (100 micrograms/ml), heat (56 degrees C, 100 degrees C) and freeze-thawing, restored
PHA
-stimulated lymphoproliferation. Dialysis of H238 cCM showed that the molecular weight of the suppressor lies between 15 and 25 kDa. Northern blot analysis demonstrated the presence of a TGF-beta transcript in H238 cells. Neutralization of the H238 cCM with monoclonal antibody to TGF-beta resulted in complete abrogation of suppressive activity in spleen cell lymphoblastogenesis. These results suggest that TGF-beta appears to be the main inhibitor of immune responses found in this HSV-2-induced murine tumor cell line. Such tumor-induced modulations may contribute to the outcome of immunotherapy in the tumor-bearing host.
...
PMID:Suppression of immune responses by herpes virus type 2-transformed murine tumor cells. 166 30
It has recently been shown that human T-cell subpopulation can be identified functionally via surface receptors for Fc fragment of immunoglobulins. We detected peripheral blood T-cells bearing the Fc receptor for IgG molecules (T gamma cell) in patients with brain tumors who manifested a variety of immunological abnormalities. We also analyzed immunological values of T gamma cells which were thought to be suppressor and/or a part of killer T cells, comparing with other immunological parameters. The percentage of T gamma cells was significantly higher in patients with malignant brain tumors than in normal controls (6.54 +/- 1.6%). The values of T gamma cells in patients with glioma, metastatic brain tumor, benign brain tumor were 15.4 +/- 4.8%, 14.9 +/- 3.2%, and 8.1 +/- 3.7%, respectively. In the patients with glioma, the values increased in the uncontrolled group compared with the well-controlled group. Furthermore, the values were decreased by surgical removal of the tumor. On immunological study of T gamma cells in the patients with glioma, there was a definite correlation between the values of T gamma cells and ADCC activity. Furthermore, the T gamma cells in the patients showed higher ADCC activity than in normal controls. The values of T gamma cells also correlated with blastogenesis of the peripheral blood lymphocytes by
PHA
(r = -0.742, p less than 0.001) and Con A (r = -0.662, p less than 0.001). These results suggest that T gamma cells are playing two important roles in patients with glioma such as suppressor function and ADCC activity, and that these cells may change according to the
tumor growth
.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Clinicoimmunological values of measurement of IgG-Fc receptor positive T cells in the patients with malignant brain tumors]. 293 80
Effects of dairy products (cheeses and yoghurt) on growth of transplanted murine tumors were examined in various tumor-host combinations. Suppression of
tumor growth
was observed in proportion to the duration of feeding. Peripheral lymph-node (LN) cells of mice fed dairy products showed an increment in the fluorescence intensity of Thy-1.2+ cells in FACS analysis. These cells showed an augmented
PHA
response and a remarkable antitumor effect in tumor neutralization test (Winn's assay) compared to control lymphocytes. These results suggest that dairy products enhance the activity of peripheral LN cells to suppress the
tumor growth
. Moreover, serum transfer from cheese fed mice revealed the protective effects against tumors, while that from yoghurt fed mice did not show such an effect. In the former mice, serum iron level was increased compared to control levels but antibody response to sheep erythrocytes (SRBC) was not augmented. From these results, we propose a hypothesis that lymphocytes may be activated by transferable serum factors such as iron-saturated transferrin and suppression of
tumor growth
caused by the effector-target interaction which is mediated by effector-associated transferrin in the case of cheese fed mice. In yoghurt fed mice another mechanism is suspected because of the low level of serum iron.
...
PMID:Inhibition of tumor growth by dairy products. 317 77
1
2
3
4
5
Next >>